bioMérieux Acquires Molecular Diagnostics Provider Argene

bioMérieux SA (Marcy l'Etoile, France), a company specializing in in-vitro diagnostics, acquired Argene SA (Verniolle, France) for US$60.1 million. Argene, a molecular diagnostics provider, is bioMérieux's tenth acquisition in the last five years.

Argene provides a wide range of diagnostics for infectious diseases, including quantitative tests for Cytomegalovirus, Epstein-Barr virus, and herpes simplex virus types 1 and 2. These tests are available for use on most commercial, open real-time polymerase chain reaction (PCR) platforms.

“Argene’s unique expertise and comprehensive range of diagnostics for immunocompromised patients will reinforce bioMérieux’s infectious disease offering in an important field of medicine. This acquisition will also enable us to accelerate the time to market of a broad test menu on the new molecular platform we are developing with Biocartis,” said Jean-Luc Bélingard, chairman and CEO of bioMérieux. “There is a perfect strategic fit between our companies and a shared commitment to improve patient health. We are very pleased that the Argene team will be joining bioMérieux,” he added.

Related Links:
bioMérieux
Argene